Abstract Background The phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K)/AKT
pathway is frequently activated during prostate cancer (PCa) progression through loss or …

Background Despite significant advances in molecular characterization and therapeutic
targeting of advanced prostate cancer, it remains the second most common cause of cancer …

The PI3K signaling pathway is activated in a majority of cancer types. It promotes
tumorigenesis by regulating nutrient metabolism, cell proliferation, survival, migration, and …

Despite recent advances in our understanding of the biological basis of prostate cancer, the
management of the disease, especially in the castration-resistant phase, remains a …

Abstract The PI3K/AKT/mTOR pathway is frequently activated in advanced prostate cancer,
due to loss of the tumour suppressor PTEN, and is an important axis for drug development …

Background PTEN deletion, mutation or reduced expression occurs in 63% of metastatic
prostate tumors, resulting in the activation of PI3K and its downstream targets, AKT and …

BACKGROUND In advanced stages of prostate cancer, the phosphatidylinositol‐3′ kinase
(PI3K)/Akt signaling cascade, one of the major survival pathways in the cell, is frequently …

Abstract Deregulation of phosphatidylinositol-3-kinase (PI3K)/protein kinase B
(Akt)/mammalian target of rapamycin (mTOR) signaling pathway contributes to prostate …

The reduction in androgen synthesis and the blockade of the androgen receptor (AR)
function by chemical castration and AR signaling inhibitors represent the main treatment …

Abstract The PI3K/Akt pathway is an actively pursued therapeutic target in oncology. In
prostate cancer, the activation of this pathway appears to be characteristic of many …